报价延迟最少15分钟:2025/07/17 07:44 EDT
盘前时段
|
||||
|
0.2292 
|
|
|
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.2364
|
|
|
| 价值评估 |
|
盈利(现时/预测)
1.72/-0.66
|
|
企业价值
4.14M
|
| 资产负债 |
|
每股账面净值
0.26
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
7.50K
|
|
每股收益
0.02
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
报价延迟最少15分钟：2025/07/17 07:44 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Azitra Inc is an early-stage clinical biopharmaceutical company focused on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products. Its discovery platform is screened for naturally occurring bacterial cells with beneficial effects. These microbes are then genomically sequenced and engineered to make cellular therapies, recombinant therapeutic proteins, peptides, and small molecules for the precision treatment of dermatology diseases. The company's product candidates include ATR-12, for treating the orphan disease and Netherton syndrome; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash; and ATR-01, a potential treatment for ichthyosis vulgaris, a chronic, abnormally dry, scaly skin disease. |
